Albumin plus furosemide versus furosemide alone for fluid overload in critically ill adults
Official title: "Comparison of Furosemide Versus Albumin Plus Furosemide in Increasing Urine Output in Critically Ill Patients: A Double-Blind Randomized Clinical Trial"
Run by Hospital H+ Queretaro · NCT07417969 · Data updated 2026-11-12
This test tries to see if giving albumin with furosemide helps adults in the ICU with fluid overload make more urine and protect kidney function compared with furosemide alone.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 56 (estimated) |
| Sponsor | Hospital H+ Queretaro Academic / other |
| Locations | 1 site (Querétaro City, Querétaro) |
| Status | Recruiting |
| Started | June 1, 2025 |
| Main results expected | September 30, 2026 |
| Study ends | October 31, 2026 |
| Registry record updated | June 16, 2026 |
| Trial ID | NCT07417969 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult ICU patients (age ≥18) who are not mechanically ventilated, are starting diuretic therapy for clinical fluid overload, and are not on renal replacement therapy are the ideal candidates.
✕Probably not a fit
Patients already on dialysis, those with clinical hypovolemia or dehydration, those receiving palliative care, or those who refuse participation are unlikely to receive benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized interventional study compares two diuretic strategies in adult ICU patients with clinical fluid overload: furosemide alone versus furosemide combined with albumin. Participants are adults not on mechanical ventilation who are starting diuretics for fluid overload, and standardized dosing schedules are used. The trial measures urine output at 2 hours as the primary early endpoint and monitors renal perfusion markers, serum and urine biochemistry, and bedside ultrasound assessments of volume status. Hemodynamic variables, electrolyte changes, and estimated glomerular filtration rate are followed to capture short-term renal and circulatory effects.
Why it matters
Potential benefit: If successful, adding albumin could increase early urine output and improve renal perfusion, potentially reducing fluid-related complications in the ICU.
How similar studies have gone: Previous smaller studies have shown mixed results—albumin can enhance diuresis in some hypoalbuminemic patients, but evidence in broad critically ill populations is limited and inconsistent.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults ≥18 years * Critically ill patients admitted to the intensive care unit (ICU) * Presence of oliguria defined as urine output \<0.5 mL/kg/hour for at least 6 hours Exclusion Criteria: * Refusal to participate by the patient or legal representative * Patients receiving palliative or end-of-life care * Acute or chronic kidney failure requiring ongoing renal replacement therapy at enrollment * Chronic dialysis dependency * Participation in another interventional clinical trial * Pregnant or lactating women
Where it's running
-
76000
Querétaro City, Querétaro, Mexico Recruiting
Study contacts
- Study coordinator: Alina Elizabeth Arechiga Casas, MD
- Email: alieliac26@gmail.com
- Phone: +52 8781360564
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.